KPTI
Karyopharm Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$162.54M
P/E Ratio
—
EPS
$-17.93
Beta
0.40
52W High
$10.99
52W Low
$3.65
50-Day MA
$7.62
200-Day MA
$6.27
Dividend Yield
—
Profit Margin
-134.20%
Forward P/E
—
PEG Ratio
-0.15
About Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc., a pharmaceutical company, is dedicated to the discovery, development and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts.
Fundamentals
| Revenue (TTM) | $146.07M |
| Gross Profit (TTM) | $14.50M |
| EBITDA | $-90.41M |
| Operating Margin | -52.40% |
| Return on Equity | -891.00% |
| Return on Assets | -41.60% |
| Revenue/Share (TTM) | $13.36 |
| Book Value | $-16.00 |
| Price-to-Book | 12.05 |
| Price-to-Sales (TTM) | 1.11 |
| EV/Revenue | 2.075 |
| EV/EBITDA | -1.85 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 11.60% |
| Shares Outstanding | $22.54M |
| Float | $15.08M |
| % Insiders | 4.82% |
| % Institutions | 51.81% |
Analyst Ratings
Consensus ($11.00 target)
2
Strong Buy4
Buy1
HoldData last updated: 4/8/2026